Biogen Idec has struck a deal with Switzerland's Neurimmune Therapeutics to develop antibodies that attack the amyloid beta plaque fingered as a prime culprit in the neurodegenerative symptoms of Alzheimer's. Neurimmune will employ its technology platform to identify antibodies that bind to the plaque in exchange for up to $380 million in total fees and milestones. There are no therapies approved to slow or stop the disease.
- see Biogen's release
- here's the AFX report for more info